Logo image of ASRT

ASSERTIO HOLDINGS INC (ASRT) Stock Fundamental Analysis

NASDAQ:ASRT - Nasdaq - US04546C2052 - Common Stock - Currency: USD

0.6224  -0.01 (-1.19%)

Fundamental Rating

3

ASRT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. ASRT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ASRT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ASRT has reported negative net income.
ASRT had a positive operating cash flow in the past year.
In the past 5 years ASRT reported 4 times negative net income.
Of the past 5 years ASRT 4 years had a positive operating cash flow.
ASRT Yearly Net Income VS EBIT VS OCF VS FCFASRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

With a decent Return On Assets value of -7.58%, ASRT is doing good in the industry, outperforming 72.22% of the companies in the same industry.
With a decent Return On Equity value of -17.82%, ASRT is doing good in the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
ROA -7.58%
ROE -17.82%
ROIC N/A
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ASRT Yearly ROA, ROE, ROICASRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 68.61%, ASRT is in the better half of the industry, outperforming 73.23% of the companies in the same industry.
ASRT's Gross Margin has declined in the last couple of years.
ASRT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
ASRT Yearly Profit, Operating, Gross MarginsASRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASRT has more shares outstanding
ASRT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ASRT has a worse debt to assets ratio.
ASRT Yearly Shares OutstandingASRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ASRT Yearly Total Debt VS Total AssetsASRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -2.50, we must say that ASRT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.50, ASRT is in line with its industry, outperforming 46.46% of the companies in the same industry.
The Debt to FCF ratio of ASRT is 1.47, which is an excellent value as it means it would take ASRT, only 1.47 years of fcf income to pay off all of its debts.
ASRT's Debt to FCF ratio of 1.47 is amongst the best of the industry. ASRT outperforms 94.95% of its industry peers.
A Debt/Equity ratio of 0.32 indicates that ASRT is not too dependend on debt financing.
ASRT has a Debt to Equity ratio (0.32) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 1.47
Altman-Z -2.5
ROIC/WACCN/A
WACC9.59%
ASRT Yearly LT Debt VS Equity VS FCFASRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

ASRT has a Current Ratio of 1.77. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
ASRT has a Current ratio of 1.77. This is in the lower half of the industry: ASRT underperforms 63.13% of its industry peers.
ASRT has a Quick Ratio of 1.43. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
ASRT's Quick ratio of 1.43 is on the low side compared to the rest of the industry. ASRT is outperformed by 65.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.43
ASRT Yearly Current Assets VS Current LiabilitesASRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

ASRT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.23%, which is quite impressive.
ASRT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.83%.
Measured over the past years, ASRT shows a very negative growth in Revenue. The Revenue has been decreasing by -11.45% on average per year.
EPS 1Y (TTM)77.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
Revenue 1Y (TTM)-17.83%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%-2.43%

3.2 Future

ASRT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.26% yearly.
Based on estimates for the next years, ASRT will show a small growth in Revenue. The Revenue will grow by 4.16% on average per year.
EPS Next Y21.06%
EPS Next 2Y35.82%
EPS Next 3Y30.49%
EPS Next 5Y35.26%
Revenue Next Year-5.11%
Revenue Next 2Y2.72%
Revenue Next 3Y2.11%
Revenue Next 5Y4.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ASRT Yearly Revenue VS EstimatesASRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ASRT Yearly EPS VS EstimatesASRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ASRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASRT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASRT Price Earnings VS Forward Price EarningsASRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

98.99% of the companies in the same industry are more expensive than ASRT, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.26
EV/EBITDA -7.15
ASRT Per share dataASRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

ASRT's earnings are expected to grow with 30.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.82%
EPS Next 3Y30.49%

More info and screens

0

5. Dividend

5.1 Amount

ASRT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSERTIO HOLDINGS INC

NASDAQ:ASRT (4/25/2025, 12:02:08 PM)

0.6224

-0.01 (-1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners29.96%
Inst Owner Change0%
Ins Owners1.17%
Ins Owner Change4.58%
Market Cap59.61M
Analysts82
Price Target2.87 (361.12%)
Short Float %5.76%
Short Ratio13.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-54.52%
Min EPS beat(2)-145.1%
Max EPS beat(2)36.06%
EPS beat(4)1
Avg EPS beat(4)-48.75%
Min EPS beat(4)-145.1%
Max EPS beat(4)36.06%
EPS beat(8)1
Avg EPS beat(8)-494.59%
EPS beat(12)5
Avg EPS beat(12)-295.24%
EPS beat(16)7
Avg EPS beat(16)-216.06%
Revenue beat(2)1
Avg Revenue beat(2)4.61%
Min Revenue beat(2)-0.83%
Max Revenue beat(2)10.04%
Revenue beat(4)3
Avg Revenue beat(4)4.61%
Min Revenue beat(4)-0.83%
Max Revenue beat(4)10.04%
Revenue beat(8)5
Avg Revenue beat(8)-0.64%
Revenue beat(12)9
Avg Revenue beat(12)1.87%
Revenue beat(16)13
Avg Revenue beat(16)3.29%
PT rev (1m)-4.26%
PT rev (3m)-7.18%
EPS NQ rev (1m)-157.18%
EPS NQ rev (3m)-157.18%
EPS NY rev (1m)-154.29%
EPS NY rev (3m)-154.29%
Revenue NQ rev (1m)-5.11%
Revenue NQ rev (3m)-9.76%
Revenue NY rev (1m)-6.82%
Revenue NY rev (3m)-6.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.48
P/FCF 2.26
P/OCF 2.26
P/B 0.49
P/tB 1.47
EV/EBITDA -7.15
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.28
FCFY44.3%
OCF(TTM)0.28
OCFY44.3%
SpS1.3
BVpS1.26
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.58%
ROE -17.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.61%
FCFM 21.13%
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
F-Score3
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 1.47
Debt/EBITDA 5.51
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion 374.79%
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.43
Altman-Z -2.5
F-Score3
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)16.81%
Cap/Depr(5y)10.15%
Cap/Sales(3y)3.56%
Cap/Sales(5y)2.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
EPS Next Y21.06%
EPS Next 2Y35.82%
EPS Next 3Y30.49%
EPS Next 5Y35.26%
Revenue 1Y (TTM)-17.83%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%-2.43%
Revenue Next Year-5.11%
Revenue Next 2Y2.72%
Revenue Next 3Y2.11%
Revenue Next 5Y4.16%
EBIT growth 1Y-215.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year180.95%
EBIT Next 3Y63.98%
EBIT Next 5Y43.56%
FCF growth 1Y-45.61%
FCF growth 3Y69.74%
FCF growth 5Y-21.57%
OCF growth 1Y-46.76%
OCF growth 3Y68.7%
OCF growth 5Y-21.83%